Review




Structured Review

Shanghai Yuanye Biochemicals dox
Doxorubicin loading, release profile, and in vitro antitumor efficacy of <t>dual-targeted</t> <t>OMVs.</t> (A) Schematic illustration of the preparation of (GPC3 + <t>CD133)ᵀ-OMVs@DOX.</t> (B) Loading efficiency (LE) and drug content (DC) of (GPC3 + CD133)ᵀ-OMVs@DOX at different initial DOX concentrations. (C) In vitro DOX release profiles from (GPC3 + CD133)ᵀ-OMVs@DOX in PBS at pH 7.4 and pH 5.0. (D) Hydrodynamic diameter of (GPC3 + CD133)ᵀ-OMVs after DOX loading, as measured by DLS. (E) Cellular uptake of free DOX (red) and PKH67-labeled (green) (GPC3 + CD133)ᵀ-OMVs@DOX by Huh-7 cells after 6 h incubation. Scale bar: 100 μm. (F) Cell viability of Huh-7 cells treated with various concentrations of free DOX or (GPC3 + CD133)ᵀ-OMVs@DOX for 24 h, as determined by CCK-8 assay. (G) Cell viability of Huh-7 cells treated with different formulations at a concentration of 18.62 μM (IC50 of free DOX) for 24 h. Data are presented as mean ± SD ( n = 6). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Dox, supplied by Shanghai Yuanye Biochemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/dox/pmc12955658-72-0-4
Average 86 stars, based on 1 article reviews
dox - by Bioz Stars, 2026-11
86/100 stars

Images

1) Product Images from "GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma"

Article Title: GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma

Journal: International Journal of Pharmaceutics: X

doi: 10.1016/j.ijpx.2026.100510

Doxorubicin loading, release profile, and in vitro antitumor efficacy of dual-targeted OMVs. (A) Schematic illustration of the preparation of (GPC3 + CD133)ᵀ-OMVs@DOX. (B) Loading efficiency (LE) and drug content (DC) of (GPC3 + CD133)ᵀ-OMVs@DOX at different initial DOX concentrations. (C) In vitro DOX release profiles from (GPC3 + CD133)ᵀ-OMVs@DOX in PBS at pH 7.4 and pH 5.0. (D) Hydrodynamic diameter of (GPC3 + CD133)ᵀ-OMVs after DOX loading, as measured by DLS. (E) Cellular uptake of free DOX (red) and PKH67-labeled (green) (GPC3 + CD133)ᵀ-OMVs@DOX by Huh-7 cells after 6 h incubation. Scale bar: 100 μm. (F) Cell viability of Huh-7 cells treated with various concentrations of free DOX or (GPC3 + CD133)ᵀ-OMVs@DOX for 24 h, as determined by CCK-8 assay. (G) Cell viability of Huh-7 cells treated with different formulations at a concentration of 18.62 μM (IC50 of free DOX) for 24 h. Data are presented as mean ± SD ( n = 6). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Figure Legend Snippet: Doxorubicin loading, release profile, and in vitro antitumor efficacy of dual-targeted OMVs. (A) Schematic illustration of the preparation of (GPC3 + CD133)ᵀ-OMVs@DOX. (B) Loading efficiency (LE) and drug content (DC) of (GPC3 + CD133)ᵀ-OMVs@DOX at different initial DOX concentrations. (C) In vitro DOX release profiles from (GPC3 + CD133)ᵀ-OMVs@DOX in PBS at pH 7.4 and pH 5.0. (D) Hydrodynamic diameter of (GPC3 + CD133)ᵀ-OMVs after DOX loading, as measured by DLS. (E) Cellular uptake of free DOX (red) and PKH67-labeled (green) (GPC3 + CD133)ᵀ-OMVs@DOX by Huh-7 cells after 6 h incubation. Scale bar: 100 μm. (F) Cell viability of Huh-7 cells treated with various concentrations of free DOX or (GPC3 + CD133)ᵀ-OMVs@DOX for 24 h, as determined by CCK-8 assay. (G) Cell viability of Huh-7 cells treated with different formulations at a concentration of 18.62 μM (IC50 of free DOX) for 24 h. Data are presented as mean ± SD ( n = 6). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Techniques Used: In Vitro, Labeling, Incubation, CCK-8 Assay, Concentration Assay

In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).
Figure Legend Snippet: In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).

Techniques Used: In Vivo, Injection, Fluorescence, Imaging, Labeling, Ex Vivo, Immunohistochemical staining, Staining, Control

Biosafety evaluation of SsnB-pretreated and dual-targeted OMVs@DOX in tumor-bearing mice. (A) Serum levels of ALT and AST as markers of liver function. (B) Serum levels of creatinine (Cr) and Urea as markers of kidney function. (C) Representative hematoxylin and eosin (H&E)-stained sections of major organs (liver, spleen, kidneys, and heart) collected at the end of the treatment period. Scale bars: 100 μm. The H-E staining of the organs from other groups could be seen in Fig. S4. Arrows indicate atrophied myocardial cells. Data are presented as mean ± SD (n = 5). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Figure Legend Snippet: Biosafety evaluation of SsnB-pretreated and dual-targeted OMVs@DOX in tumor-bearing mice. (A) Serum levels of ALT and AST as markers of liver function. (B) Serum levels of creatinine (Cr) and Urea as markers of kidney function. (C) Representative hematoxylin and eosin (H&E)-stained sections of major organs (liver, spleen, kidneys, and heart) collected at the end of the treatment period. Scale bars: 100 μm. The H-E staining of the organs from other groups could be seen in Fig. S4. Arrows indicate atrophied myocardial cells. Data are presented as mean ± SD (n = 5). Statistical significance is denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001.

Techniques Used: Staining

Related Articles

Sonication:

Article Title: GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma
Article Snippet: Images were acquired using fluorescence microscopy (LSM 780; Zeiss, Germany) and analyzed with ImageJ software (National Institute of Health, USA). .. DOX ( S17092 , Shanghai Yuanye, China) was loaded into OMVs using a sonication method. ..

other:

Article Title: Yiqi Fumai lyophilized injection attenuates doxorubicin-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats by inhibition of oxidative stress, inflammation and apoptosis
Article Snippet: DOX was obtained from Shanghai Yuanye Biological Technology Co., Ltd (Shanghai, China).

Concentration Assay:

Article Title: The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk.
Article Snippet: Most of the studies on doxycycline (DOX) and florfenicol (FF) remain focused on the improvement of antimicrobial activity and antimicrobial spectrum, and there is no relevant report on whether there is interaction between the two drugs after the combination.. This research study evaluated the effect of DOX on FF metabolism in vitro and its mechanisms.. The findings of this study showed that DOX inhibits FF metabolism in two ways.

CCK-8 Assay:

Article Title: The "steric-like" inhibitory effect and mechanism of doxycycline on florfenicol metabolism: Interaction risk.
Article Snippet: Most of the studies on doxycycline (DOX) and florfenicol (FF) remain focused on the improvement of antimicrobial activity and antimicrobial spectrum, and there is no relevant report on whether there is interaction between the two drugs after the combination.. This research study evaluated the effect of DOX on FF metabolism in vitro and its mechanisms.. The findings of this study showed that DOX inhibits FF metabolism in two ways.



Similar Products

98
TargetMol dox ferrostatin 1
Dox Ferrostatin 1, supplied by TargetMol, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Ferrostatin-1/pmc13769180-52-17-22
Average 98 stars, based on 1 article reviews
dox ferrostatin 1 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

98
MedChemExpress dox
Dox, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Doxorubicin+hydrochloride/pm42822757-59-6-11
Average 98 stars, based on 1 article reviews
dox - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

96
MedChemExpress dox ftb h tanespimycin
Dox Ftb H Tanespimycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Tanespimycin/pm42624205-59-52-67
Average 96 stars, based on 1 article reviews
dox ftb h tanespimycin - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

98
MedChemExpress doxorubicin dox
Doxorubicin Dox, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Doxorubicin+hydrochloride/pm42822314-45-11-16
Average 98 stars, based on 1 article reviews
doxorubicin dox - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

99
Inotiv doxycycline dox chow
A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with <t>doxycycline</t> (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.
Doxycycline Dox Chow, supplied by Inotiv, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Teklad+Irradiated+Global+Diet+2918/bio_rxiv__64898__2026__09__25__754416-310-6-9
Average 99 stars, based on 1 article reviews
doxycycline dox chow - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
TargetMol doxorubicin hydrochloride dox
A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with <t>doxycycline</t> (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.
Doxorubicin Hydrochloride Dox, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Doxorubicin+hydrochloride/pmc13615627-43-0-8
Average 97 stars, based on 1 article reviews
doxorubicin hydrochloride dox - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

97
TargetMol doxorubicin dox
A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with <t>doxycycline</t> (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.
Doxorubicin Dox, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Doxorubicin/pmc13604901-58-11-28
Average 97 stars, based on 1 article reviews
doxorubicin dox - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

98
MedChemExpress doxorubicin hydrochloride dox
A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with <t>doxycycline</t> (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.
Doxorubicin Hydrochloride Dox, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/Doxorubicin+hydrochloride/10__1016_slash_j__cej__2026__182455-66-0-9
Average 98 stars, based on 1 article reviews
doxorubicin hydrochloride dox - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

99
Hitachi Ltd dox
(A) Schematic Illustration of <t>the</t> <t>M1@MS/MnO</t> 2 <t>/DOX/NO</t> Preparation Process and (B) The mechanism of M1@MS/MnO 2 /DOX/NO for the Combination of RNS- and ROS-Mediated Oxidative Therapy for HCC Treatment
Dox, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dox/HT7800/pmc13625094-35-5-14
Average 99 stars, based on 1 article reviews
dox - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with doxycycline (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.

Journal: bioRxiv

Article Title: Mycobacterium tuberculosis requires riboflavin biosynthesis for survival in the host

doi: 10.64898/2026.09.25.754416

Figure Lengend Snippet: A. Experiment design. C57BL/6 mice were infected with ∼100 CFU of WT Erdman or ribA2 Tet-OFF by aerosol. At the indicated times (day 0, day 10 or week 6), groups mice were treated with doxycycline (dox; 2,000 ppm in chow), which was maintained for the duration of the experiment. Groups of mice ( n =6, 3M, 3F) were euthanized at the indicated time points to collect lungs and spleen. B-E. CFU enumeration in lung ( B, D ) and spleen ( C, E ) homogenates by serial dilution and plating on 7H10 agar (WT) or 7H10 with 53 μM riboflavin ( ribA2 Tet-OFF). Data are means ± SEM ( n =6). Blue “nd” indicates none detected for ribA2 Tet-OFF +dox d0. Asterisks indicate significant differences from the WT no dox control ( B, C ) or from the ribA2 Tet-OFF no dox control ( D, E ) by Welch’s t -test (24 hr and 1 wk lung data) or by one-way ANOVA with Dunnett’s multiple comparisons test post-hoc. * P <0.05, ** P <0.001.

Article Snippet: Groups of mice were treated with doxycycline (dox) chow (Teklad Global 2018 diet containing 2,000 ppm dox; Envigo) starting at the following times: day 0 (immediately after infection), day 10 or day 42 (week 6) for C57BL/6 mice; day 21 (week 3) or day 42 (week 6) for C3HeB/FeJ mice.

Techniques: Infection, Aerosol, Serial Dilution, Control

(A) Schematic Illustration of the M1@MS/MnO 2 /DOX/NO Preparation Process and (B) The mechanism of M1@MS/MnO 2 /DOX/NO for the Combination of RNS- and ROS-Mediated Oxidative Therapy for HCC Treatment

Journal: ACS Omega

Article Title: Synergistic ROS/RNS-Mediated Chemotherapy via M1 Macrophage Membrane-Functionalized Nanovesicles for Targeted Hepatocellular Carcinoma Treatment

doi: 10.1021/acsomega.6c04069

Figure Lengend Snippet: (A) Schematic Illustration of the M1@MS/MnO 2 /DOX/NO Preparation Process and (B) The mechanism of M1@MS/MnO 2 /DOX/NO for the Combination of RNS- and ROS-Mediated Oxidative Therapy for HCC Treatment

Article Snippet: The morphology of M1@MS/MnO 2 /DOX/NO was characterized by transmission electron microscopy (TEM, HT7700, Hitachi).

Techniques:

Nanomedicine characterizations. Transmission electron microscopy (TEM) image showing the spherical morphology of (A) MS/MnO 2 /DOX/NO and (B) M1@MS/MnO 2 /DOX/NO observed by TEM. The scale bar is 200 nm. (C) Zeta of M1@MS/MnO 2 /DOX/NO by measuring the changes of (D) particle size of MS/MnO 2 /DOX/NO and M1@MS/MnO 2 /DOX/NO. (E) Quantitative determination of DOX and NO donor ( tert -butyl nitrite) loading efficiencies (%) quantified via UV–vis spectrophotometry at 485 and 340 nm, respectively. (F) In vitro release of DOX from M1@MS/MnO 2 /DOX/NO at different concentrations of GSH. The experimental results represent the mean ± SD ( n = 3).

Journal: ACS Omega

Article Title: Synergistic ROS/RNS-Mediated Chemotherapy via M1 Macrophage Membrane-Functionalized Nanovesicles for Targeted Hepatocellular Carcinoma Treatment

doi: 10.1021/acsomega.6c04069

Figure Lengend Snippet: Nanomedicine characterizations. Transmission electron microscopy (TEM) image showing the spherical morphology of (A) MS/MnO 2 /DOX/NO and (B) M1@MS/MnO 2 /DOX/NO observed by TEM. The scale bar is 200 nm. (C) Zeta of M1@MS/MnO 2 /DOX/NO by measuring the changes of (D) particle size of MS/MnO 2 /DOX/NO and M1@MS/MnO 2 /DOX/NO. (E) Quantitative determination of DOX and NO donor ( tert -butyl nitrite) loading efficiencies (%) quantified via UV–vis spectrophotometry at 485 and 340 nm, respectively. (F) In vitro release of DOX from M1@MS/MnO 2 /DOX/NO at different concentrations of GSH. The experimental results represent the mean ± SD ( n = 3).

Article Snippet: The morphology of M1@MS/MnO 2 /DOX/NO was characterized by transmission electron microscopy (TEM, HT7700, Hitachi).

Techniques: Transmission Assay, Electron Microscopy, Morphology, Spectrophotometry, In Vitro

In vitro therapeutic efficacy and apoptosis-inducing capability of M1@MS/MnO 2 /DOX/NO in LM3 cells. (A) Cell viability of LM3 cells following treatment with various formulations (M1@MS/MnO 2 , M1@MS/MnO 2 /DOX, M1@MS/MnO 2 /NO, DOX/NO, and M1@MS/MnO 2 /DOX/NO) as determined by the MTS assay ( n = 5). (B) Quantitative analysis of the total apoptotic rates derived from flow cytometry ( n = 3). (C) Representative Annexin V-FITC/PI flow cytometry scatter plots illustrating the distribution of cell populations after corresponding treatments. Data are expressed as mean ± SD. Statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 compared to the untreated control group.

Journal: ACS Omega

Article Title: Synergistic ROS/RNS-Mediated Chemotherapy via M1 Macrophage Membrane-Functionalized Nanovesicles for Targeted Hepatocellular Carcinoma Treatment

doi: 10.1021/acsomega.6c04069

Figure Lengend Snippet: In vitro therapeutic efficacy and apoptosis-inducing capability of M1@MS/MnO 2 /DOX/NO in LM3 cells. (A) Cell viability of LM3 cells following treatment with various formulations (M1@MS/MnO 2 , M1@MS/MnO 2 /DOX, M1@MS/MnO 2 /NO, DOX/NO, and M1@MS/MnO 2 /DOX/NO) as determined by the MTS assay ( n = 5). (B) Quantitative analysis of the total apoptotic rates derived from flow cytometry ( n = 3). (C) Representative Annexin V-FITC/PI flow cytometry scatter plots illustrating the distribution of cell populations after corresponding treatments. Data are expressed as mean ± SD. Statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001 compared to the untreated control group.

Article Snippet: The morphology of M1@MS/MnO 2 /DOX/NO was characterized by transmission electron microscopy (TEM, HT7700, Hitachi).

Techniques: In Vitro, Drug discovery, MTS Assay, Analysis, Derivative Assay, Flow Cytometry, Control

Cellular uptake of various nanoformulations by hepatocellular carcinoma cells as evaluated by confocal laser scanning microscopy and flow cytometry. (A) Representative confocal laser scanning microscopy fluorescence tracks in LM3 cells following a 2 h incubation with membrane-deficient MS/MnO 2 /DOX/NO or biomimetic M1@MS/MnO 2 /DOX/NO nanoparticles. Green fluorescence signals represent FITC-labeled nanoformulations, and blue fluorescence denotes DAPI-counterstained nuclei. Scale bar = 20 μm. (B) Flow cytometric analysis of the cellular uptake of different nanoformulations. (C) Quantitative analysis of mean fluorescence intensity derived from the flow cytometry data. Data are presented as mean ± SD ( n = 3). Statistical significance is indicated as *** p < 0.001.

Journal: ACS Omega

Article Title: Synergistic ROS/RNS-Mediated Chemotherapy via M1 Macrophage Membrane-Functionalized Nanovesicles for Targeted Hepatocellular Carcinoma Treatment

doi: 10.1021/acsomega.6c04069

Figure Lengend Snippet: Cellular uptake of various nanoformulations by hepatocellular carcinoma cells as evaluated by confocal laser scanning microscopy and flow cytometry. (A) Representative confocal laser scanning microscopy fluorescence tracks in LM3 cells following a 2 h incubation with membrane-deficient MS/MnO 2 /DOX/NO or biomimetic M1@MS/MnO 2 /DOX/NO nanoparticles. Green fluorescence signals represent FITC-labeled nanoformulations, and blue fluorescence denotes DAPI-counterstained nuclei. Scale bar = 20 μm. (B) Flow cytometric analysis of the cellular uptake of different nanoformulations. (C) Quantitative analysis of mean fluorescence intensity derived from the flow cytometry data. Data are presented as mean ± SD ( n = 3). Statistical significance is indicated as *** p < 0.001.

Article Snippet: The morphology of M1@MS/MnO 2 /DOX/NO was characterized by transmission electron microscopy (TEM, HT7700, Hitachi).

Techniques: Confocal, Laser-Scanning Microscopy, Flow Cytometry, Fluorescence, Incubation, Membrane, Labeling, Analysis, Derivative Assay

Antitumor efficiency was evaluated by in vitro experiments. (A) Photographic records of the excised subcutaneous LM3 tumors harvested from BALB/c male nude mice at the end of the 15-day therapeutic regimen (B) Dynamic progression curves tracking relative tumor volume modifications (% of initial volume) recorded across a 15-day timeline under systemic administrations of saline, M1@MS/MnO 2 , M1@MS/MnO 2 /DOX, M1@MS/MnO 2 /NO, DOX/NO, or M1@MS/MnO 2 /DOX/NO. (C) Representative histological images of LM3 tumor slices after different treatments using H&E staining (scale bar = 100 μm). (** P < 0.01, **** P < 0.0001).

Journal: ACS Omega

Article Title: Synergistic ROS/RNS-Mediated Chemotherapy via M1 Macrophage Membrane-Functionalized Nanovesicles for Targeted Hepatocellular Carcinoma Treatment

doi: 10.1021/acsomega.6c04069

Figure Lengend Snippet: Antitumor efficiency was evaluated by in vitro experiments. (A) Photographic records of the excised subcutaneous LM3 tumors harvested from BALB/c male nude mice at the end of the 15-day therapeutic regimen (B) Dynamic progression curves tracking relative tumor volume modifications (% of initial volume) recorded across a 15-day timeline under systemic administrations of saline, M1@MS/MnO 2 , M1@MS/MnO 2 /DOX, M1@MS/MnO 2 /NO, DOX/NO, or M1@MS/MnO 2 /DOX/NO. (C) Representative histological images of LM3 tumor slices after different treatments using H&E staining (scale bar = 100 μm). (** P < 0.01, **** P < 0.0001).

Article Snippet: The morphology of M1@MS/MnO 2 /DOX/NO was characterized by transmission electron microscopy (TEM, HT7700, Hitachi).

Techniques: In Vitro, Saline, Staining